AEON — Aeon Biopharma Cashflow Statement
0.000.00%
- $4.53m
- $16.21m
- 2
- 100
- 15
- 32
Annual cashflow statement for Aeon Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K/A | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -55.6 | -52.6 | -385 | 42 |
Depreciation | ||||
Non-Cash Items | 25.8 | 10.6 | 339 | -63.1 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 1.42 | 6.27 | -2.74 | 0.706 |
Change in Prepaid Expenses | ||||
Change in Accounts Payable | ||||
Change in Accrued Expenses | ||||
Net Change in Other Assets & Liabilities | ||||
Cash from Operating Activities | -28.4 | -35.6 | -47.8 | -20.3 |
Capital Expenditures | -0.17 | -0.306 | 0 | — |
Purchase of Fixed Assets | ||||
Cash from Investing Activities | -0.17 | -0.306 | 0 | — |
Financing Cash Flow Items | -1.44 | 0 | — | — |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 13.6 | 40.5 | 14 | 15.1 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -15 | 4.62 | -33.8 | -5.14 |